Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338292 | 0.88 | SIGMAR1 (0.54) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL6154697 | 0.82 | EPHX1 (0.47) | SIGMAR1EPHX1NPC1EPHX2 | |
| SCHEMBL2740853 | 0.81 | SIGMAR1 (0.53) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL28484903 | 0.79 | SIGMAR1 (0.52) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL3919418 | 0.79 | SIGMAR1 (0.52) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL28482705 | 0.79 | SIGMAR1 (0.52) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL2740855 | 0.79 | SIGMAR1 (0.52) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL28482525 | 0.79 | SIGMAR1 (0.52) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL28484902 | 0.79 | SIGMAR1 (0.52) | SIGMAR1EPHX1SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL6154846 | 0.78 | SIGMAR1 (0.50) | SIGMAR1EPHX1CYP3A4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912575-B1 | PROCESSES FOR THE SYNTHESIS OF CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITORY ACTIVITY | EURO CELTIQUE SA (LU) | 2005-02-02 | — | — | EP | claimed |
| EP-0940139-B1 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | SCION PHARMACEUTICALS INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-5864037-A | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity | EURO-CELTIQUE, S.A. (LU) | 1999-01-26 | — | — | US | claimed |
| US-5837737-A | MODULATOR OF NEUROTRANSMITTERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-11-17 | — | — | US | claimed |
| US-5652269-A | MODULATION OF NEUROTRANSMITTER RELEASE, NEUROPROTECTIVE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-07-29 | — | — | US | claimed |
| US-5403861-A | Treating or preventing nerve cell death | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-04-04 | — | — | US | claimed |
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0940139-B1 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | SCION PHARMACEUTICALS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | disclosed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | disclosed |
| EP-1169321-A4 | PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY | EURO CELTIQUE SA (LU) | 2002-10-30 | — | — | EP | disclosed |
| US-6413975-B1 | DISEASES WITH HIGH LEVELS OF INFLAMMATORY CYTOKINES; ASTHMA; ALLERGIES; INFLAMMATION; DEPRESSION; ALZHEIMER'S DISEASE; VASCULAR AND MULTI-IN-FARCT DEMENTIA | EURO-CELTIQUE, S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| US-5622968-A | ADMINISTERING TO BLOCK VOLTAGE SENSITIVE CALCIUM CHANNELS OF MAMMALIAN NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5614630-A | NEUROTRANSMITTER RELEASE MODULATOR | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5403861-A | Treating or preventing nerve cell death | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | SIGMAR1 3775/4885EPHX1 1847/4885SMN1; SMN2 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.